Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 2 opinions in the last 12 months.
Carl Zeiss Meditec, trading under the symbol AFX-O, is currently facing a volatile market scenario. After reaching a peak in March 2024, the stock has experienced a downturn attributed to weaker sales in China and North America. The company's core offerings, which include surgical microscope lenses and laser surgery equipment, have the potential for recovery as Chinese sales are showing signs of improvement. Analysts remain optimistic about the stock, indicating a price target of 83.58 Euros, supported by its asset-light business model and significant cash reserves. The company is currently trading at a PE ratio of 13x for 2026, suggesting favorable conditions should US interest rates decline.
They make lenses for microscopes used by surgeons, and mirrors for ASML. Share are down from 150 Euros due to slowing sales in China and North America. They also make laser surgery equipment. But it's an asset-lite company with tons of cash. It trades at 13x PE 2026. If interest rate decline, they will benefit.
Carl Zeiss Meditec is a OTC stock, trading under the symbol AFX-O on the (). It is usually referred to as or AFX-O
In the last year, 3 stock analysts published opinions about AFX-O. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Carl Zeiss Meditec.
Carl Zeiss Meditec was recommended as a Top Pick by on . Read the latest stock experts ratings for Carl Zeiss Meditec.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Carl Zeiss Meditec published on Stockchase.
On , Carl Zeiss Meditec (AFX-O) stock closed at a price of $.
All his past picks on this date were small-caps and chosen, based on him expecting US interest rates to fall. All were turnaround plays. He used dollar-cost averaging. AFX peaked in March 2024, fell in July and since up slightly. Is turning around now. Fell because Chinese sales weakened, but that is recovering now. Is buying more.